First-in-Human CAR-T test for tough cancers halted early

NCT ID NCT07108140

Summary

This was a very early, small pilot study to test the safety of a new CAR-T cell therapy for patients with advanced solid tumors that have a specific protein called ALPP. The study involved only 5 patients who had already tried other treatments without success. The main goal was to find the highest safe dose and check for side effects, but the trial was terminated early.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • The Jinling Hospital

    Nanjing, Jiangsu, China

Conditions

Explore the condition pages connected to this study.